Antidepressant effect of geranylgeranylacetone in a chronic mild stress model of depression and its possible mechanism

Experimental and Therapeutic Medicine

Volumn 4, Issue 4, 2012, Pages 627-632

  Zhong, Jing Mei ^a   Wu, Shao Yuan ^a   Bai, Jie ^b   Guo, Qiang ^a   Tao, Jian ^a   Chen, Hui ^a   Zhao, Nai Wei ^a   Zhao, Zhong ^a   Fu, Hao ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Depression; Geranylgeranylacetone; Heat shock protein 70; Monoamine oxidase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CASPASE 3; HEAT SHOCK PROTEIN 70; TEPRENONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; APOPTOSIS; ARTICLE; CHRONIC MILD STRESS; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; HIPPOCAMPUS; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; PROTEIN EXPRESSION; RAT;

EID: 84865359458     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.669     Document Type: Article

References (54)

1. Kessler RC, Berglund P, Demler O, et al: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105, 2003.
2. Nemeroff CB: The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 41: 189-206, 2007.
3. Rosen RC and Marin H: Prevalence of antidepressant-associated erectile dysfunction. J Clin Psychiatry 64 (Suppl 10): 5-10, 2003.
4. Evans CG, Chang L and Gestwicki JE: Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem 53: 4585-4602, 2010.
5. Parsell DA and Lindquist S: The function of heat-shock proteins in stress tolerance: degradation and reactivation of damaged proteins. Annu Rev Genet 27: 437-496, 1993.
6. Sharp FR, Massa SM and Swanson RA: Heat-shock protein protection. Trends Neurosci 22: 97-99, 1999.
7. Ooie T, Takahashi N, Saikawa T, et al: Single oral dose of geranylgeranylacetone induces heat-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation 104: 1837-1843, 2001.
8. Guo S, Wharton W, Moseley P and Shi H: Heat shock protein 70 regulates cellular redox status by modulating glutathione-related enzyme activities. Cell Stress Chaperones 12: 245-254, 2007.
9. Kimmins S and MacRae TH: Maturation of steroid receptors: an example of functional cooperation among molecular chaperones and their associated proteins. Cell Stress Chaperones 5: 76-86, 2000.
10. Rajapandi T, Greene LE and Eisenberg E: The molecular chaperones Hsp90 and Hsc70 are both necessary and sufficient to activate hormone binding by glucocorticoid receptor. J Biol Chem 275: 22597-22604, 2000.
11. Shimizu S, Nomura K, Ujihara M, et al: An allel-specific abnormal transcript of the heat shock protein 70 gene in patients with major depression. Biochem Biophys Res Commun 219: 745-752, 1996.
12. Martini F, Fernández C, Segundo LS, Tarazona JV and PablosMV: Assessment of potential immunotoxic effects caused by cypermethrin, fluoxetine, and thiabendazole using heat shock protein 70 and interleukin-1beta mRNA expression in the anuran Xenopus laevis. Environ Toxicol Chem 29: 2536-2543, 2010.
13. Yu J, Roh S, Lee JS, et al: The effects of venlafaxine and dexamethasone on the expression of HSP70 in rat C6 glioma cells. Psychiatry Investig 7: 43-48, 2010.
14. Allagui MS, Nciri R, Rouhaud MF, et al: Long-term exposure to low lithium concentrations stimulates proliferation, modifies stress protein expression pattern and enhances resistance to oxidative stress in SH-SY5Y cells. Neurochem Res 34: 453-462, 2009.
15. Hirakawa T, Rokutan K, Nikawa T and KishiK: Geranyl-geranylacetone induces heat shock proteins in cultured guinea pig gastric mucosal cells and rat gastric mucosa. Gastroenterology111: 345-357, 1996.
16. Ishii Y, Kwong JM and Caprioli J: Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci 44: 1982-1992, 2003.
17. Latchman DS: Heat shock proteins and cardiac protection. Cardiovasc Res 51: 637-646, 2001.
18. Yamagami K, Yamamoto Y, Ishikawa Y, Yonezawa K, ToyokuniS and Yamaoka Y: Effects of geranyl-geranyl-acetone administration before heat shock preconditioning for conferring tolerance against ischemia-reperfusion injury in rat livers. J Lab Clin Med 135: 465-475, 2000.
19. Katsuno M, Sang C, Adachi H, et al: Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci USA 102: 16801-16806, 2005.
20. Tanito M, Kwon YW, Kondo N, et al: Cytoprotective effects of geranylgeranylacetone against retinal photooxidative damage. J Neurosci 25: 2396-2404, 2005.
21. Yasuda H, Shichinohe H, Kuroda S, Ishikawa T and IwasakiY: Neuroprotective effect of a heat shock protein inducer, geranylgeranylacetone in permanent focal cerebral ischemia. Brain Res 1032: 176-182, 2005.
22. Luo FC, Qi L, Lv T, et al: Geranylgeranylacetone protects mice against morphine-induced hyperlocomotion, rewarding effect, and withdrawal syndrome. Free Radic Biol Med 52: 1218-1227, 2012.
23. Meyer JH, Ginovart N, Boovariwala A, et al: Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry 63: 1209-1216, 2006.
24. Duman RS: Depression: a case of neuronal life and death? Biol Psychiatry 56: 140-145, 2004.
25. Manji HK, Drevets WC and Charney DS: The cellular neurobiology of depression. Nat Med 7: 541-547, 2001.
26. Mathew SJ, Manji HK and Charney DS: Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 33: 2080-2092, 2008.
27. Elhwuegi AS: Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 28: 435-451, 2004.
28. Du L, Faludi G, Palkovits M, Sotonyi P, Bakish D and HrdinaPD: High activity-related allele of MAO-A gene associated with depressed suicide in males. Neuroreport 13: 1195-1198, 2002.
29. Wouters J: Structural aspects of monoamine oxidase and its reversible inhibition. Curr Med Chem 5: 137-162, 1998.
30. Riederer P, Lachenmayer L and Laux G: Clinical applications of MAO-inhibitors. Curr Med Chem 11: 2033-2043, 2004.
31. Terano A, Shiga J, Hiraishi H, Ota S and Sugimoto T: Protective action of tetraprenylacetone against ethanol-induced damage in rat gastric mucosa. Digestion 35: 182-188, 1986.
32. Hirota K, Nakamura H, Arai T, et al: Geranylgeranylacetone enhances expression of thioredoxin and suppresses ethanol-induced cytotoxicity in cultured hepatocytes. Biochem Biophys Res Commun 275: 825-830, 2000.
33. Bremner JD: Does stress damage the brain? Biol Psychiatry 45: 797-805, 1999.
34. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL and CharneyDS: Hippocampal volume reduction in major depression. Am J Psychiatry 157: 115-118, 2000.
35. Colla M, Kronenberg G, Deuschle M, et al: Hippocampal volume reduction and HPA-system activity in major depression. J Psychiatr Res 41: 553-560, 2007.
36. Eastwood SL and Harrison PJ: Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a western blot study of synaptophysin, GAP-43 and the complexins. Brain Res Bull 55: 569-578, 2001.
37. Lenze E, Cross D, McKeel D, Neuman RJ and Sheline YI: White matter hyperintensities and gray matter lesions in physically healthy depressed subjects. Am J Psychiatry 156: 1602-1607, 1999.
38. Nolan CL, Moore GJ, Madden R, et al: Prefrontal cortical volume in childhood-onset major depression: preliminary findings. Arch Gen Psychiatry 59: 173-179, 2002.
39. Ongür D, Drevets WC and Price JL: Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 95: 13290-13295, 1998.
40. Bachis A, Cruz MI, Nosheny RL and Mocchetti I: Chronic unpredictable stress promotes neuronal apoptosis in the cerebral cortex. Neurosci Lett 442: 104-108, 2008.
41. Gould E and Tanapat P: Stress and hippocampal neurogenesis. Biol Psychiatry 46: 1472-1479, 1999.
42. McEwen BS: Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 87: 873-904, 2007.
43. Lee AL, Ogle WO and Sapolsky RM: Stress and depression: possible links to neuron death in the hippocampus. Bipolar Disord 4: 117-128, 2002.
44. Woo M, Hakem R, Soengas MS, et al: Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 12: 806-819, 1998.
45. Salvesen GS: Caspases: opening the boxes and interpreting the arrows. Cell Death Differ 9: 3-5, 2002.
46. Ghavami S, Hashemi M, Ande SR, et al: Apoptosis and cancer: mutations within caspase genes. J Med Genet 46: 497-510, 2009.
47. Ghribi O, Herman MM and Savory J: The endoplasmic reticulum is the main site for caspase-3 activation following aluminum-induced neurotoxicity in rabbit hippocampus. Neurosci Lett 324: 217-221, 2002.
48. Shiraishi H, Okamoto H, Yoshimura A and Yoshida H: ER stress-induced apoptosis and caspase-12 activation occurs downstream of mitochondrial apoptosis involving Apaf-1. J Cell Sci 119: 3958-3966, 2006.
49. Kim YH, Song JJ, Kim YC, et al: Geranylgeranylacetone ameliorates acute cochlear damage caused by 3-nitropropionic acid. Neurotoxicology 31: 317-325, 2010.
50. Mikuriya T, Sugahara K, Sugimoto K, et al: Attenuation of progressive hearing loss in a model of age-related hearing loss by a heat shock protein inducer, geranylgeranylacetone. Brain Res 1212: 9-17, 2008.
51. Fujiki M, Kobayashi H, Abe T and Ishii K: Astroglial activation accompanies heat shock protein upregulation in rat brain following single oral dose of geranylgeranylacetone. Brain Res 991: 254-257, 2003.
52. Mosser DD, Caron AW, Bourget L, et al: The chaperone function of hsp70 is required for protection against stress-induced apoptosis. Mol Cell Biol 20: 7146-7159, 2000.
53. Yin HY, Ma XF, Liu F, Xia M and Xu AT: Protective effect of geranylgeranylacetone on cisplatin ototoxicity. Chemotherapy 55: 1-5, 2009.
54. Li CY, Lee JS, Ko YG, Kim JI and Seo JS: Heat shock protein 70 inhibits apoptosis downstream of cytochrome c release and upstream of caspase-3 activation. J Biol Chem 275: 25665-25671, 2000.